Evertec (NYSE:EVTC) reported quarterly earnings of $0.65 per share which met the analyst consensus estimate. This is a 9.72 percent decrease over earnings of $0.72 per share from the same period last year. The company reported quarterly sales of $161.79 million which beat the analyst consensus estimate of $155.05 million by 4.35 percent. This is a 4.22 percent increase over sales of $155.24 million the same period last year.
Autolus Therapeutics’ Obe-Cel’s Shows Compelling Safety Over Gilead’s Drug For Acute Lymphoblastic Leukemia
Truist has raised the price target for Autolus Therapeutics PLC (NASDAQ: AUTL) from $6 to $9
